Jenny Stanford Publishing
774 pages | 34 Color Illus. | 74 B/W Illus.
The relationship between biocatalysis and the different areas of pharmaceutics is discussed in volumes 4 to 6 of Pan Stanford Series on Biocatalysis.
Volume 4 provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, the main regulatory authorities, rare diseases and orphan drugs, the costs of drug development and therapies, and the use of enzymes in downstream processing of pharmaceuticals. Examples of therapeutic enzyme inhibitors discussed are carbonic anhydrase inhibitors together with their multiple drug interactions, carboxylesterase inhibitors and human diseases, and the application of (multifunctional) inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer’s disease. The text also covers engineered proteins and bioactive peptides as therapeutic formulations and fibrinolytic enzymes for thrombolytic therapy. Different chapters discuss the enzymes employed for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology.
Pharmaceuticals: Some General Aspects
Use of Enzymes in the Downstream Processing of Biopharmaceuticals
Duarte Miguel F. T. Prazeres
Therapeutic Use of Carbonic Anhydrase Inhibitors and Their Multiple Drug Interactions
Andrea Angeli and Claudiu T. Supuran
Fibrinolytic Enzymes for Thrombolytic Therapy
Swaroop S Kumar, Sabu Abdulhameed
Role of Engineered Proteins as Therapeutic Formulations
Khushboo Gulati and Krishna Mohan Poluri
Synthesis of bioactive peptides for pharmaceutical applications
Jaison Jeevanandam et al.
Cardiovascular Disease and Oxidative Stress
Marco Fernandes, Alisha Patel, and Holger Husi
Enzymatic Amino Acid Deprivation Therapies Targeting Cancer
Carla S. S. Teixeira et al.
Carboxylesterase inhibitors: Relevance for Pharmaceutical Applications
Li-Wei Zou abd Guang-Bo Ge
Molecular Aspects of the Activity and Inhibition of the FAD-containing Monoamine Oxidases
Rona R. Ramsay
Multifunctional Monoamine Oxidase and Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease
Ireen Denya, Sarel F. Malan, and Jacques Joubert
The Neurodegenerative Characteristics of Alzheimer’s Disease and Related Multi-Target Drug Design Studies
Hayrettin Ozan Gülcan, and Ilkay Erdogan Orhan
Aldehyde Oxidases as Enzymes in Phase I Drug Metabolism
Cristiano Mota et al.
Cytochrome P450 Enzymes for the Synthesis of Novel and Known Drugs and Drug Metabolites
Sanjana Haque et al.
Cytochromes P450, Cardiovascular Homeostasis and Disease
Chin Eng Ong et al.
Protein Degradation Inducers SNIPERs and PROTACs against Oncogenic Proteins
Norihito Shibata et al.
Resistance Mechanisms of Tumor Cells
Biocatalytic Nanoreactors for Medical Purposes
Oscar González-Davis, Kanchan Chauhan, and Rafael Vazquez-Duhalt
Computer-Aided Drug Design for the Identification of Multi-Target Directed Ligands (MTDLs) in Complex Diseases: An Overview
Pravin Ambure and Kunal Roy
The Development of Improved Therapeutics through a Glycan-‘Designer’ Approach
Natalia G. Bednarska
On Biocatalysis as Resourceful Methodology for Complex Syntheses: Selective Catalysis, Cascades, and Biosynthesis
Andreas Sebastian Klein, Thomas Classen, and Jörg Pietruszka